What is Biogen's finite lived intangible assets - gross?

Biogen (BIIB) reported finite lived intangible assets - gross of $14.08B in Q1 2026.

How has Biogen's finite lived intangible assets - gross changed year-over-year?

Biogen's finite lived intangible assets - gross decreased by 0.2% year-over-year, from $14.10B to $14.08B.

What is the long-term trend for Biogen's finite lived intangible assets - gross?

Over 5 years (2020 to 2025), Biogen's finite lived intangible assets - gross has grown at a 13.7% compound annual growth rate (CAGR), from $7.39B to $14.07B.

What does finite lived intangible assets - gross mean?

The total original cost of intangible assets that have a limited lifespan, before subtracting accumulated amortization.

Discontinued — last reported Q4 '17

Non-Current Assets

Finite Lived Intangible Assets - Gross

Biogen Finite Lived Intangible Assets - Gross increased by 0.1% to $14.08B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.2%, from $14.10B to $14.08B. Over 5 years (FY 2020 to FY 2025), Finite Lived Intangible Assets - Gross shows an upward trend with a 13.7% CAGR.

Analysis

StatementBalance Sheet Statement

SectionNon-Current Assets

CategoryCapital Allocation

SignalContext dependent

VolatilityStable

First reportedQ3 2015

Last reportedQ4 2017

How to read this metric

An increase typically signals recent strategic acquisitions or significant investment in intellectual property, while a decrease reflects asset retirement or impairment.

Detailed definition

This is the total historical cost of intangible assets with a defined useful life, such as patents, trademarks, and acqu...

Peer comparison

Large healthcare companies frequently carry significant gross intangible assets due to the high volume of M&A activity in the sector.

Metric ID: finite_lived_intangible_assets_gross

Historical Data

12 periods

	Q4 '21	Q4 '22	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$7.41B	$7.42B	$11.73B	$14.03B	$14.06B	$14.10B	$14.14B	$14.10B	$14.09B	$14.09B	$14.07B	$14.08B
QoQ Change	—	+0.0%	+58.2%	+19.6%	+0.3%	+0.3%	+0.3%	-0.2%	-0.1%	+0.0%	-0.1%	+0.1%
YoY Change	—	+0.0%	+58.2%	—	—	—	+20.5%	+0.5%	+0.2%	-0.1%	-0.5%	-0.2%

Range$7.41B – $14.14B

CAGR+26.3%

Avg YoY Growth+9.8%

Median YoY Growth+0.1%

Finite Lived Intangible Assets - Gross at Other Companies

MedtronicMDT View metric

Frequently Asked Questions

What is Biogen's finite lived intangible assets - gross?: Biogen (BIIB) reported finite lived intangible assets - gross of $14.08B in Q1 2026.
How has Biogen's finite lived intangible assets - gross changed year-over-year?: Biogen's finite lived intangible assets - gross decreased by 0.2% year-over-year, from $14.10B to $14.08B.
What is the long-term trend for Biogen's finite lived intangible assets - gross?: Over 5 years (2020 to 2025), Biogen's finite lived intangible assets - gross has grown at a 13.7% compound annual growth rate (CAGR), from $7.39B to $14.07B.
What does finite lived intangible assets - gross mean?: The total original cost of intangible assets that have a limited lifespan, before subtracting accumulated amortization.